Shearman And Sterling

News May 01, 2015

Shearman & Sterling Represents Underwriters in $3.5 Billion Notes Offering by Amgen

Shearman & Sterling represented Morgan Stanley, BofA Merrill Lynch, Credit Suisse, Goldman, Sachs & Co., Barclays, Citigroup, Deutsche Bank Securities, J.P. Morgan and SMBC Nikko as joint book-running managers in connection with Amgen’s registered offering of $3.5 billion of investment grade notes, consisting of $750,000,000 of 2.125% senior notes due 2020, $500,000,000 of 2.700% senior notes due 2022, $1,000,000,000 of 3.125% senior notes due 2025 and $1,250,000,000 of 4.400% senior notes due 2045. Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

The following Shearman & Sterling team advised the underwriters in the transaction: partners John Wilson (San Francisco-Capital Markets), Laurence Crouch (Menlo Park-Tax) and Richard Hsu (Menlo Park-IP), counsel Eileen O’Pray (Menlo Park-Tax) and Emily Griffen (San Francisco-Litigation), and associates Nathan Mee (San Francisco-Capital Markets), Antonio Herrera Cuevas (San Francisco-Capital Markets), Scott Lucas (San Francisco-Capital Markets) and Benjamin Petersen (Menlo Park-IP).